Rapport Therapeutics, Inc. Common Stock

Four clinical-stage biotech companies are approaching potentially important mid- to late-stage data readouts this fall, with outcomes that could reshape their pipelines and valuations. Kodiak Sciences is on track to report top-line data this month from the phase III DAYBREAK study evaluating Zenkuda (tarcocimab tedromer) and KSI-501 for treatment-naïve wet age-related macular degeneration against Regeneron's Eylea, targeting a roughly $15-billion anti-VEGF market. Celldex Therapeutics expects a September/October 2026 top-line readout from its phase III EMBARQ-CSU1 and EMBARQ-CSU2 studies of barzolvolimab in chronic spontaneous urticaria, with 1,939 patients enrolled and a planned regulatory submission in 2027. Rapport Therapeutics is targeting October 2026 for phase II results on RAP-219 in bipolar mania, while Vaxcyte expects top-line safety, tolerability and immunogenicity data from the phase III OPUS-1 study of its 31-valent pneumococcal conjugate vaccine VAX-31 by the end of October 2026. Among the four, Kodiak carries a Zacks Rank #4 (Sell), while Celldex, Rapport and Vaxcyte each hold a Zacks Rank #3 (Hold).